Characterizing CDK12-Mutated Prostate Cancers
Abstract
Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated mCRPC, presenting clinical, genomic, and tumor-infiltrating lymphocyte (TIL) data.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 15, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-2371
Entities
People
- Adam Sharp
- Alec Paschalis
- Ana Ferreira
- Bora Gurel
- Carlo Messina
- Christina Guo
- Claudia Bertan
- Diletta Bianchini
- George Seed
- Ines Figueiredo
- Jan Rekowski
- Joaquin Mateo
- Johann de Bono
- Juliet Carmichael
- Khobe Chandran
- Maialen Barrero
- Maria D. Fenor De La Maza
- Maryou Lambros
- Mateus Crespo
- Mattia Rediti
- Nuria Porta
- Pasquale Rescigno
- Rita Pereira
- Ruth Riisnaes
- Susana Miranda
- Suzanne Carreira
- Yuan Wei
Organizations
- Cancer Research UK
- Department of Health and Social Care
- Prostate Cancer Foundation
- Prostate Cancer UK
- Stand Up to Cancer
- Vall d'Hebron Institute of Oncology